BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35305098)

  • 1. Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary.
    Fusco MJ; Knepper TC; Balliu J; Del Cueto A; Laborde JM; Hooda SM; Brohl AS; Bui MM; Hicks JK
    Oncologist; 2022 Feb; 27(1):e9-e17. PubMed ID: 35305098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
    Hayashi H; Takiguchi Y; Minami H; Akiyoshi K; Segawa Y; Ueda H; Iwamoto Y; Kondoh C; Matsumoto K; Takahashi S; Yasui H; Sawa T; Onozawa Y; Chiba Y; Togashi Y; Fujita Y; Sakai K; Tomida S; Nishio K; Nakagawa K
    JAMA Oncol; 2020 Dec; 6(12):1931-1938. PubMed ID: 33057591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.
    Varghese AM; Arora A; Capanu M; Camacho N; Won HH; Zehir A; Gao J; Chakravarty D; Schultz N; Klimstra DS; Ladanyi M; Hyman DM; Solit DB; Berger MF; Saltz LB
    Ann Oncol; 2017 Dec; 28(12):3015-3021. PubMed ID: 29045506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.
    Boscolo Bielo L; Belli C; Crimini E; Repetto M; Ascione L; Pellizzari G; Santoro C; Fuorivia V; Barberis M; Fusco N; Rocco EG; Curigliano G
    Oncologist; 2024 Jun; 29(6):504-510. PubMed ID: 38520742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report.
    Mitani Y; Kanai M; Kou T; Kataoka S; Doi K; Matsubara J; Ohashi S; Matsumoto S; Muto M
    BMC Cancer; 2020 Dec; 20(1):1177. PubMed ID: 33267781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
    Dermawan JK; Rubin BP
    Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.
    Pauli C; Bochtler T; Mileshkin L; Baciarello G; Losa F; Ross JS; Pentheroudakis G; Zarkavelis G; Yalcin S; Özgüroğlu M; Beringer A; Scarato J; Mueller-Ohldach M; Thomas M; Moch H; Krämer A
    Oncologist; 2021 May; 26(5):e769-e779. PubMed ID: 33687747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
    Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
    J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary.
    Wang X; Beharry A; Sheffield BS; Cheema PK
    Oncologist; 2023 Jun; 28(6):474-478. PubMed ID: 36933203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome.
    Bochtler T; Endris V; Leichsenring J; Reiling A; Neumann O; Volckmar AL; Kirchner M; Allgäuer M; Schirmacher P; Krämer A; Stenzinger A
    Int J Cancer; 2019 Dec; 145(11):2963-2973. PubMed ID: 30963573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer of Unknown Primary in the Molecular Era.
    Kato S; Alsafar A; Walavalkar V; Hainsworth J; Kurzrock R
    Trends Cancer; 2021 May; 7(5):465-477. PubMed ID: 33516660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown.
    Kato S; Gumas S; Adashek JJ; Okamura R; Lee S; Sicklick JK; Kurzrock R
    Mol Oncol; 2024 Apr; 18(4):956-968. PubMed ID: 35866362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
    Schipper LJ; Samsom KG; Snaebjornsson P; Battaglia T; Bosch LJW; Lalezari F; Priestley P; Shale C; van den Broek AJ; Jacobs N; Roepman P; van der Hoeven JJM; Steeghs N; Vollebergh MA; Marchetti S; Cuppen E; Meijer GA; Voest EE; Monkhorst K
    ESMO Open; 2022 Dec; 7(6):100611. PubMed ID: 36463731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.
    Lorkowski SW; Dermawan JK; Rubin BP
    Virchows Arch; 2024 Feb; 484(2):369-375. PubMed ID: 37999736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review.
    Lombardo R; Tosi F; Nocerino A; Bencardino K; Gambi V; Ricotta R; Spina F; Siena S; Sartore-Bianchi A
    Front Oncol; 2020; 10():533. PubMed ID: 32457826
    [No Abstract]   [Full Text] [Related]  

  • 16. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
    Rassy E; Pavlidis N
    Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study.
    Huey RW; Shah AT; Reddi HV; Dasari P; Topham JT; Hwang H; Dhillon N; Willett A; Smaglo BG; Estrella JS; Rashid A; Matamoros A; Overman MJ; Choquette L; Omerza G; Kelly K; Wang X; Loree JM; Rueter J; Varadhachary GR; Raghav K
    J Natl Cancer Inst; 2023 Aug; 115(8):994-997. PubMed ID: 37202363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer of unknown primary.
    Lee MS; Sanoff HK
    BMJ; 2020 Dec; 371():m4050. PubMed ID: 33288500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.
    Johnson DB; Dahlman KH; Knol J; Gilbert J; Puzanov I; Means-Powell J; Balko JM; Lovly CM; Murphy BA; Goff LW; Abramson VG; Crispens MA; Mayer IA; Berlin JD; Horn L; Keedy VL; Reddy NM; Arteaga CL; Sosman JA; Pao W
    Oncologist; 2014 Jun; 19(6):616-22. PubMed ID: 24797823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.